Axitinib, Sorafenib Provide Comparable Survival in mRCC Patients
VIENNA—Axitinib therapy is linked with an general survival (OS) related to that of sorafenib therapy as second-line remedy of metastatic renal cell carcinoma (mRCC), according to updated findings presented at the European Society for Medical …
Read more on Renal and Urology News
Lauded kidney cancer drug obtainable
All 723 individuals with advanced renal cell carcinoma had stopped responding to earlier therapies. Dr Tom Powles, consultant oncologist at Barts Well being NHS Trust in London, who took element in the Axis trial, stated: "Today's news marks an important step …
Read far more on The Press Association
AVEO and Astellas Announce New Data Presented at ESMO 2012 Congress …
… announced new data from the Phase 3 TIVO-1 trial (TIvozanib Versus sOrafenib in 1st line advanced RCC) demonstrating the security and tolerability profile of tivozanib versus sorafenib in the initial line setting for patients with metastatic renal cell …
Read a lot more on DailyFinance
Leave a Reply
You must be logged in to post a comment.